Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.00p +1.72% 118.50p 117.00p 120.00p 118.50p 116.50p 116.50p 36,133 09:58:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -0.3 - 60.86

Verona Pharma Share Discussion Threads

Showing 12651 to 12672 of 12675 messages
Chat Pages: 507  506  505  504  503  502  501  500  499  498  497  496  Older
DateSubjectAuthorDiscuss
13/7/2017
11:45
HTTP://investors.veronapharma.com/static-files/794b4b7f-0ce7-4203-81c0-c93ec4c2860c
bewise2
27/6/2017
08:30
Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory approval in five European countries, comprising the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic, for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD). The trial is expected to commence in the third quarter of 2017, with top-line data expected in the second half of 2018.
bewise2
23/6/2017
17:37
Anybody intending to go to the shareholders meeting next week?
bewise2
23/6/2017
08:31
Is this a new low for the share price
kwizza
23/6/2017
08:10
American adventure turned sour?
ewads
24/5/2017
16:13
Equities research analysts at Stifel Nicolaus assumed coverage on shares of Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) in a research note issued on Monday. The firm set a “buy” rating and a $22.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 35.30% from the company’s current price
aishah
24/5/2017
15:38
Pleased to see 150p barrier broken. Time for a partial EIS exit and let the rest run.
127tolmers
23/5/2017
15:17
May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference. An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
bewise2
23/5/2017
10:28
Nasdaq listing and placing all done. City switches from short to long. C'est tout simple.
phowdo
23/5/2017
10:13
Jefferies International initiated with a BUY and 250p target.
aishah
23/5/2017
10:03
What is occurring?
bonzo
28/4/2017
07:50
The Nasdaq ticker is VRNA http://www.nasdaq.com/symbol/vrna I'll have a go at changing the header to accommodate an additional real time Nasdaq chart.
timbo003
27/4/2017
10:06
A floor of 132p has now been set by the NASDAQ offer. Hopefully the price quickly moves to a 15% premium post offer and breaks through the 150p barrier and provides a sensible post EIS exit price.
127tolmers
26/4/2017
00:34
http://www.nasdaq.com/markets/ipos/company/verona-pharma-plc-999545-83296
bewise2
19/4/2017
09:26
http://m.nasdaq.com/article/respiratory-biotech-verona-pharma-sets-terms-for-75-million-us-ipo-cm775580
bewise2
18/4/2017
10:27
Timbo, I couldn't go either. I was looking forward to your write up. The 3 year EIS lock-in is over but trading is thin. I guess the 150p (3p in old money)level is going to be a key indicator on sentiment
127tolmers
18/4/2017
10:05
Timbo,I attended the AGM, it was mentioned that the real money was in PDI &MDI and when Verona were in talks with the Chinese they wanted to see a hand held device. Which Verona are I the process of looking at. Could this have any bearing on things ?
aimshares
18/4/2017
09:46
Thanks for spotting that Kwizza I have fixed the main link to Verona's web site, although I see that there are also a few others (on the Verona web site) which now need updating, I have rectified a couple of them and will look at the rest when I have a bit more time later this week.
timbo003
18/4/2017
09:02
timbo, the link to Verona website above is not working, could you have a look
kwizza
18/4/2017
08:40
I couldn't make it to the AGM this year (I had it down in my diary for the day before), but I look forward to seeing the AGM slides on the web site. Today's announcement has me a bit puzzled With the IND effective, the Company plans to initiate a PK clinical trial in the middle of this year in approximately 12 healthy volunteers to determine the oral bioavailability of RPL554, as well as assess the safety and tolerability of the drug. Top-line data is expected in the fourth quarter of 2017. Are Verona considering developing an oral dosage form?
timbo003
07/4/2017
16:34
...not looking so good today?
haff1
04/4/2017
07:06
VRP true to their word (not usual for AIM). All the makings for the offer being oversubscribed too.
ewads
Chat Pages: 507  506  505  504  503  502  501  500  499  498  497  496  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170722 06:45:35